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A recent high-density linkage screen confirmed that the HLA complex contains the strongest genetic factor for the risk of
multiple sclerosis (MS). In parallel, a linkage disequilibrium analysis using 650 single nucleotide polymorphisms (SNP) markers
of the HLA complex mapped the entire genetic effect to the HLA-DR-DQ subregion, reflected by the well-established risk
haplotype HLA-DRB1*15,DQB1*06. Contrary to this, in a cohort of 1,084 MS patients and 1,347 controls, we show that the
HLA-A gene confers an HLA-DRB1 independent influence on the risk of MS (P=8.4610
210). This supports the opposing view,
that genes in the HLA class I region indeed exert an additional influence on the risk of MS, and confirms that the class I allele
HLA-A*02 is negatively associated with the risk of MS (OR=0.63, P=7610
212) not explained by linkage disequilibrium with
class II. The combination of HLA-A and HLA-DRB1 alleles, as represented by HLA-A*02 and HLA-DRB1*15, was found to
influence the risk of MS 23-fold. These findings imply complex autoimmune mechanisms involving both the regulatory and the
effector arms of the immune system in the triggering of MS.
Citation: Brynedal B, Duvefelt K, Jonasdottir G, Roos IM, A ˚kesson E, et al (2007) HLA-A Confers an HLA-DRB1 Independent Influence on the Risk of
Multiple Sclerosis. PLoS ONE 2(7): e664. doi:10.1371/journal.pone.0000664
INTRODUCTION
The human leukocyte antigen (HLA) gene complex on chromosome
6 has been linked to and associated with several supposedly
autoimmune diseases. This highly variable region harbors over
420 genes[1] and has been unambiguously associated with multiple
sclerosis (MS, MIM 126200) susceptibility since 1972[2]. Extensive
polymorphism and linkage disequilibrium (LD) complicates the
efforts to precisely map associations with MS in this region but most
evidence has pointed to the class II region and the HLA-
DRB1(GeneID: 3123) and -DQB1 genes, and specifically to the
haplotype DRB1*1501,DRB5*0101,DQA1*0102,DQB1*0602[3].
Recently, Lincoln and colleagues reported data on 4,203
individuals from 1,185 Canadian and Finnish MS families
genotyped for approximately 650 SNP markers spanning the
HLA complex and its flanking regions, in all 13 Mb[4]. Strong
associations were observed with several LD blocks within the HLA
class II subregion. Conditioning for HLA-DRB1 revealed that all
block or SNP associations were dependent on the HLA-DRB1
gene, implying that the HLA associated MS susceptibility is
determined by HLA class II alleles or closely located variants [4].
However, this study did not assess any functional gene variants
besides HLA-DRB1, such as the HLA-A gene (GeneID: 3105). Also,
most likely due to the difficulty of designing assays against SNP
markers in highly polymorphic genes, no SNP within or close to
HLA-A were genotyped. The original reports on HLA associations
with MS were indeed focused on the HLA class I specificities HLA-
A and HLA-B [2,5]. Somewhat later, when class II specificities
were discovered and the strong association between HLA-DRB1
and MS emerged, the class I associations were regarded as
secondary [6]. More recently the possible importance of HLA class
I genes in MS susceptibility has been re-investigated by us and
others [7–9]. Fogdell-Hahn and co-workers examined the role of
classical HLA genes including both class I (HLA-A, -B, -C) and
class II (HLA-DRB1, -DQ, -DP), indicating that HLA-A*03 confers
a risk for MS while HLA-A*02 has a protective effect [7]. This
primary study, as well as that of Harbo and co-workers [8], was
too limited in size to establish a possible independence from the
influence of class II alleles due to LD. Further, in addition to the
classical association with the HLA-DRB1*15-carrying haplotype,
recent studies have identified a more complex situation where
several HLA-DRB1 alleles interact in determining the risk of MS
[10,11]. In the present study, we set out to investigate how alleles
of the HLA-DRB1 and HLA-A genes interact in determining the
risk of MS. In order to distinguish the importance of two
multiallelic loci, in addition to a sufficiently large sample size,
a statistic strategy needs to be applied where the effect of one allele
can be evaluated in the presence of other effects. Here, we use
multiple logistic regression models enabling simultaneous analysis
of all included alleles while adjusting for the potential confounding
effect due to LD [12]. Thus, we were able to establish an HLA-
DRB1 independent effect of HLA-A in MS susceptibility.
MATERIALS AND METHODS
The 1,084 MS patients included in this study were diagnosed by
neurologists at the Karolinska University Hospital and fulfilled the
McDonald criteria of MS[13], their mean age was 51.5 years. The
control group consisted of 1,347 consecutively collected blood
donors with a mean age of 45.6. The study population was
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PLoS ONE | www.plosone.org 1 July 2007 | Issue 7 | e664residents of the Stockholm area and predominantly Swedish,
including a few percent from other Scandinavian countries but
excluding persons with a non-Scandinavian origin. Oral informed
consent was obtained from all participants, and the ethical board
of Karolinska Institutet approved the study. None of the included
patients or controls had been included in our previous study on
HLA class I in MS [7].
Functional alleles of HLA-A and HLA-DRB1 were identified by
use of allele specific primers [14] (Table 1). Genotypes carried by
individuals utilized as controls were in Hardy Weinberg
equilibrium [15] for both genes (data not shown). For the logistic
regression analysis, we used the methodology proposed by Cordell
and Clayton [12] in which nested hypotheses involving logistic
regression models of different loci are compared using likelihood
ratio tests. The first step was performed to establish which locus
had the strongest effect in initial models with single point effects of
HLA-A and HLA-DRB1. The following step involved adding loci
into the model until the Likelihood-Ratio Test (LRT) was non-
significant. In our analysis this meant assessing the additional effect
of HLA-A on MS susceptibility over and above the effect of HLA-
DRB1. The analysis up to this point included all alleles with
a frequency among the MS patients of .5%.
To further pinpoint the specific alleles contributing to MS
susceptibility, we applied stepwise logistic regression on an allelic
level. Starting from a model with all HLA-A and HLA-DRB1
alleles, the least significant allele was removed one at the time,
until the effect size of all remaining alleles were significant. Finally,
the last model comparison assessed whether an interaction
between HLA-DRB1 and HLA-A would improve the prediction.
For a complete description of all the models used in the analysis
see Supporting Information Table S1. It should be noted that odds
ratios obtained in a logistic regression framework are adjusted for
all the other alleles included in the model, and therefore differ
from those obtained when a given allele is compared to all other
alleles, the most commonly used comparison in previous studies.
We declared the odds ratio for a specific allele (relative to the
baseline comparators) as statistically significant if the p-value
exceeded a Bonferroni corrected threshold. The overall signifi-
cance level a, chosen to be 0.05, was divided by 11, i.e. the total
number of global tests (4) plus the total number of steps in the
stepwise allele selection (7).
RESULTS AND DISCUSSION
A model including the main effects of both HLA-A and HLA-DRB1
(model 3 in Table 2) predicted the subjects’ disease status
significantly better than the model including only HLA-DRB1
(model 2). The P-value for this comparison was 8610
210,
illustrating a strong additional effect of HLA-A on MS susceptibility
(Table 2), It should be noted that the P-value refers to the
independent effect of HLA-A, since the LD between the two loci is
accounted for by including (conditioning on) HLA-DRB1 in the
logistic regression model.
In order to pinpoint the alleles that confer an effect on MS
susceptibility, a stepwise logistic regression was performed on all
Table 1. Allele frequencies (at a resolution corresponding to
serological specificities) of HLA-A and HLA-DRB1 in MS patients
(n=1084) and healthy controls (n=1347).
......................................................................
MS HC
HLA- frequency (%) frequency (%)
A*01 14.4 13.6
A*02 26.6 35.9
A*03 21.2 17.5
A*11 5.7 5.1
A*24 9.8 8.2
AX
a 22.4 19.8
DRB1*01 6.8 11.3
DRB1*03 11.5 12.5
DRB1*04 16.0 18.9
DRB1*08 5.1 5.4
DRB1*13 10.9 14.3
DRB1*15 35.5 15.6
DRB1X
b 22.2 14.4
aAX includes all observed alleles at the HLA-A locus with frequencies of less than
5% in cases; A*23, A*25, A*26, A*29, A*30, A*31, A*32, A*33, A*66, A*68, A*69,
A*74 and A*210.
bDRB1X includes all observed alleles at the HLA-DRB1 locus with frequencies of
less than 5% in cases;DRB1*07, DRB1*09, DRB1*10, DRB1*11, DRB1*12, DRB1*14,
DRB1*16 and DRB1*103.
doi:10.1371/journal.pone.0000664.t001
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Table 2. Comparison of the nested logistic regression models of HLA-DRB1 and HLA-A
..................................................................................................................................................
Model Model terms Deviance Df
a Model comparison DDeviance
b DDf
c P-value
0 3336.4 2426
1 HLA-A
d 3286.1 2421 Model 1 vs. 0 50.3 5 1.2610
29
2 HLA-DRB1
e 3054.1 2420 Model 2 vs. 0 282.3 6 5.1610
258
3 HLA-DRB1+HLA-A
f 3003.1 2415 Model 3 vs. 2 51.05 5 8.4610
210
4 HLA-DRB1+HLA-A
g 3008.05 2422
5 HLA-DRB1 * HLA-A
h 3007.87 2419 Model 5 vs. 4 0.19 3 0.98
aDf is the degrees of freedom in the model.
bThe D Deviance is the difference is deviance between the compared models. A large value (small P-value) indicates that the smaller models does not predict the
outcome well, thus the smaller model is rejected.
cDDf is the difference in degrees of freedom between the compared models, i.e. the number of parameters restricted in the smaller model.
dIncludes main effects of all alleles at HLA-A.
eIncludes main effects of all alleles at HLA-DRB1,
fIncludes main effects of all alleles at HLA-A and -DRB1.
gReduced model with main effects of significantly associated alleles at HLA-A and -DRB1
hIncludes main effects, as well as interaction effects of significantly associated alleles at HLA-A and -DRB1
doi:10.1371/journal.pone.0000664.t002
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MS is Associated with HLA-A
PLoS ONE | www.plosone.org 2 July 2007 | Issue 7 | e664the alleles with frequency above 5%. The excluded alleles are
reported in Supporting Information Table S2, whereas the alleles
in the final model are reported in Table 3 along with corresponding
statistics. As expected, our results showed that the DRB1*15 allele
increased the risk of developing MS (OR=2.9, P,2610
216)
(Table3).The describedheterogeneity of effectsonMSsusceptibility
at the HLA-DRB1 locus [10,11] was partly confirmed, since several
DRB1 alleles show significant association (Table 3). Dyment et al
[10] reported an under-transmission of DRB1*01 to affected
offspring positive for DRB1*15,t h u st h eDRB1*01/DRB1*15
genotype would be uncommon among patients with MS. In
contrast, we observed a protective effect of HLA-DRB1*01
(OR=0.69 P=1610
23), independently of HLA-DRB1*15.S i m i l a r -
ly, a pool of less common HLA-DRB1 alleles (DRB1*07, DRB1*09,
DRB1*10, DRB1*11, DRB1*12, DRB1*14, DRB1*16 and
DRB1*103) was negatively associated with the risk of MS
(OR=0.77, P=2610
23). This was most likely an effect of one or
several of the included alleles. All DRB1X alleles had low frequency
and were combined into one entity due to expected lack of power.
At the HLA-A locus, the A*02 allele decreased the risk of MS
(OR=0.63, P=7610
212). No other HLA-A allele had an effect
that differed significantly from that of the baseline.
Our results do not confirm an independent role of HLA-A*03 in
MS susceptibility. In Table 4 we have compared our results, using
logistic regression,with Fishers exacttest and Cochran-Armitage test
for trend of genotype distribution in our material. Both unadjusted
approaches showed significant p-values for HLA-A*03 (3610
23 and
7610
24 respectively), whereas adjusting for other alleles generated
a p-value of 0.95. This may seem contradictory to previous studies
[7,8], but in fact shows the strength of the current statistical
approach; the A*03 association previously detected is presumably
a reciprocal effect of the decreased A*02 frequency or caused by
confounding from the DRB1 locus. At the HLA-DRB1 locus,
DRB1*03, DRB1*04 and DRB1*13 show significant p-values in the
unadjusted analysis, not confirmed by logistic regression, thus most
likely a reciprocal effect of the strong DRB1*15 association.
We proceeded by fitting a model with possible interactions
between the HLA-A and HLA-DRB1 loci. When comparing the
model including interaction terms (model 5) with model 4 we found
no improvement in the ability to predict the subjects’ disease status
(Table 2); the global p-value was 0.98 and none of the included
interaction terms were significant. We could therefore conclude that
the HLA-A*02 association was independent of the HLA-DRB1 locus
and specifically the DRB1*15 allele; neither LD nor interaction with
HLA-DRB1 had influenced the association of HLA-A*02 with MS.
So in contrary to the recent SNP-based LD mapping study [4], we
clearly show a HLA class I effect independent of HLA-DRB1.
It has previously been reported that HLA-DRB1*15 exerts an
allele dose effect on the risk of MS [16,17]. Figure 1 illustrates how
the genotypes of HLA-DRB1 and HLA-A jointly modified the
empirical OR’s of MS, the most susceptible genotypes (homozy-
gosity for DRB1*15 but no A*02) and most resistant (homozygosity
for A*02 but no DRB1*15) genotypes differed 23 fold in the risk of
MS. The magnitude of the risk jointly conferred by these loci greatly
exceeds the relative risk of 3.5 typically seen for carriage of HLA-
DRB1*15. This indicates that genes in the HLA region may confer
a larger fraction of the genetic aetiology of MS than previously
thought. This notion is further supported by the results of recent MS
linkage analyses; in these studies, with increasing power of the
analysis, the HLA locus has gradually obtained higher LOD scores,
eventually exceeding 11, while all other candidate loci have
remained insignificant[18,19]. Recently, Yeo and co-workers
reported an association with several alleles of HLA-DRB1, together
with a negative association with the HLA class I allele HLA-C*05 in
patients lacking DRB1 risk alleles, a finding which supports the
importance of HLA class I genes in MS [9]. However, it remains to
be studied whether the HLA-C locus contributes to MS susceptibility
in our population, and, if so, whether there may be a confounding
effect of LD between HLA-A*02 and HLA-C*05.
The HLA complex is reputed for strong LD. Therefore, a newly
reported genetic association could be expected to be secondary to
a previously known association. As explained above, this was
clearly not the case for the HLA-A association. The two global
measures used (Cramer’s V and Kendall’s tau-b) showed low levels
of LD (0.25 and -0.030 respectively). However weak, an LD of this
magnitude could potentially affect allele distributions at the linked
locus and induce a secondary association, but in the case of the
HLA-A*02 allele this possibility is rejected by the results of the
logistic regression analysis (P=8.4610
210). Pairwise LD has been
estimated and is reported in Supporting Information Tables S3
and S4. While it is principally possible that the HLA-A association
in MS is due to another genetic variant in LD with HLA-A*02,
data from the HapMap project shows that HLA-A is not part of
any sizable LD block.
Frequencies of HLA alleles are known to vary considerably
between different populations, presumably due to genetic drift and
Table 4. Comparison of p-values: logistic regression with all
alleles of HLA-DRB1 and HLA-A included simultaneously vs.
Cochran-Armitage Trend tests and Fisher’s Exact tests on one
allele at the time.
......................................................................
HLA allele P-value
a Armitage
b Fisher’s
c
A*01 0.43 0.06
A*02 6.8610
212 9.6610
212 4.4610
211
A*03 0.95
d 6.9610
24 2.7610
23
A*11 0.52
d 0.34 0.47
A*24 0.48
d 0.04 0.11
AX 0.38
d 0.03 0.07
DRB1*01 1.3610
23 1.4610
27 6.3610
27
DRB1*03 0.41
d 0.27 1.8610
24
DRB1*04 0.14
d 8.4610
23 1.9610
23
DRB1*08 0.72 0.81
DRB1*13 0.46
d 5.0610
24 1.0610
24
DRB1*15 ,2610
216 0 3.3610
258
DRB1X 1.6610
23 1.1610
211 3.6610
211
aP-values from the stepwise logistic regression analysis.
bP-value from Cochran-Armitage test of trend of genotype distribution.
cP-value from Fisher’s exact test of genotype distribution.
dThe exclusion p-values from the stepwise logistic regression, see Table S1.
doi:10.1371/journal.pone.0000664.t004
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Table 3. Alleles of HLA-A and HLA-DRB1 significantly
associated with the susceptibility to MS identified by
backward stepwise logistic regression analysis.
......................................................................
Allele OR P-value
HLA-A*02 0.63 6.8610
212
HLA-DRB1*01 0.69 1.2610
23
HLA-DRB1*15 2.9 ,2610
216
HLA-DRB1X 0.77 1.6610
23
doi:10.1371/journal.pone.0000664.t003
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PLoS ONE | www.plosone.org 3 July 2007 | Issue 7 | e664different environmental challenges. Therefore a correct random
sample of the population is important for the evaluation of HLA
associations within that population. We therefore compared the
distribution of HLA-A and HLA-DR alleles in our controls to the
HLA genotype data available from the Swedish bone marrow
registry (n=40 162 and 11 006 respectively) and found no
significant deviation. In particular, the HLA-A*02 frequencies are
highly comparable (allele frequency of 35.9% in our controls
compared to 35.3% in the Swedish bone marrow registry). Thus
we feel confident that our control group is a suitable random
sample of the Swedish population.
The HLA gene complex is different from other genomic regions
by harbouring the most polymorphic genes we know; isotypic and
allotypic polymorphism is in fact central to the physiological role
of the class I and class II molecules. Therefore, it is not surprising
that genetic association studies applying anonymous markers such
as microsatellites and SNPs [4] are less efficient in detecting
associations than the functional variants themselves.
With the present results in mind, it is reasonable to speculate
that the genetic risk is indeed influenced by a function of an HLA
class I molecule, possibly HLA-A. In contrast to the principle role
of HLA-class II molecules in the triggering of an adaptive immune
response, HLA class I antigens instead typically interact with
cytotoxic CD8+ T cells. In fact, CD8+ T cells outnumber CD4+ T
cells in MS lesions and may be of central importance in lesion
pathogenesis (reviewed in [20]). In addition, HLA class I molecules
also interact with NK cells, and are in this way important for
innate immunity.
Further mapping efforts to locate genetic effects on MS
susceptibility within this region should preferably employ func-
tional variants along with other markers. In addition, functional
studies of HLA class I molecules in MS are motivated.
To conclude; using a large case control material and simple,
straightforward statistical analysis we have shown that HLA-A
confers an additional influence on MS susceptibility in the Swedish
population, not attributable to the known HLA-DRB1 association.
This role of HLA class I genes may have important implications
for the disease triggering mechanisms in MS.
SUPPORTING INFORMATION
Table S1 Model description.
Found at: doi:10.1371/journal.pone.0000664.s001 (0.03 MB
DOC)
Table S2 Sequential exclusion of alleles in the stepwise logistic
regression procedure. At each step, the least significant allele was
removed until all remaining alleles in the model were significant
(Table 3) at a =0.05/11.
Found at: doi:10.1371/journal.pone.0000664.s002 (0.03 MB
DOC)
Table S3 Pair-wise LD measures, D’ and R2, and two global
(multi-allelic) measures of LD: Cramer’s V and Kendall’s tau-b for
alleles of HLA-A and HLA-DRB1 among controls.
Found at: doi:10.1371/journal.pone.0000664.s003 (0.05 MB
DOC)
Table S4 Pair-wise LD measures, D’ and R2, and two global
(multi-allelic) measures of LD: Cramer’s V and Kendall’s tau-b for
alleles of HLA-A and HLA-DRB1 among cases.
Found at: doi:10.1371/journal.pone.0000664.s004 (0.05 MB
DOC)
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Figure 1. Empirical odds ratios (ORs) for combinations of the HLA-DRB1*15 and HLA-A*02 alleles. A genotype of two HLA-A*02 alleles but no HLA-
DRB1*15 allele was used as baseline in the calculation of ORs. P values are reported above the bars.
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